The Scientist

» biologics

Most Recent

image: Regulations for Biosimilars

Regulations for Biosimilars

By | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

image: Gene Therapy for Brain Disease

Gene Therapy for Brain Disease

By | May 16, 2012

Delivering a missing enzyme to the brains of paralyzed children with a rare, life-threatening neurological disease restores movement and builds muscle mass.

0 Comments

image: FDA Eases Sterility Requirements

FDA Eases Sterility Requirements

By | May 16, 2012

The US Food and Drug Administration has relaxed some of the rules governing how companies must test the sterility of materials used to make biologic drugs.

1 Comment

image: Size Matters to Industry

Size Matters to Industry

By | April 11, 2012

Large molecules are more likely to make it to market these days than small molecules, according to new reports.

0 Comments

image: FDA Discusses Biosimilars

FDA Discusses Biosimilars

By | August 8, 2011

The government says regulatory requirements for generic biological therapies will have to be tailored to the treatment in question.

3 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham